10-K/A: Adicet Bio Files Amended 10-K for Fiscal Year 2025

Adicet Bio, Inc. has filed an amendment to its 2025 annual report (10-K/A) to update disclosures regarding its internal controls and procedures.

Summary

• This filing is an amendment (10-K/A) to Adicet Bio, Inc.'s annual report for the fiscal year ended December 31, 2025.
• The amendment specifically addresses and corrects an omission in Item 9A (Controls and Procedures) of the original filing.
• The company is updating disclosures related to the effectiveness of its disclosure controls and procedures as of December 31, 2025.
• Management, including the CEO and CFO, has concluded that the disclosure controls and procedures were effective as of December 31, 2025.
• Similarly, management assessed the internal control over financial reporting as of December 31, 2025, based on the COSO framework and concluded it was effective.
• The amendment does not include any new financial statements or updates to other sections of the original filing, except for Item 9A.
• The company is not required to provide an attestation report from its registered public accounting firm on internal control over financial reporting as it is a non-accelerated filer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a procedural amendment to correct an omission in controls disclosure rather than a report on financial performance or strategic developments.

Positives

• Management has affirmed the effectiveness of the company's disclosure controls and procedures as of December 31, 2025.
• Management has also affirmed the effectiveness of the company's internal control over financial reporting as of December 31, 2025.
• The company has corrected an omission in its previous filing, demonstrating a commitment to accurate and complete disclosure.

Negatives

• The original filing inadvertently omitted key statements regarding the effectiveness of disclosure controls and procedures, requiring an amendment.
• The company acknowledges inherent limitations in internal control systems, including the possibility of human error and overriding of controls, which could lead to future misstatements.

Risks

• The company cannot assure that material weaknesses or significant deficiencies will not occur in the future or that they can be remediated in a timely manner, which could impair its ability to report financial information accurately.
• Inherent limitations in internal control systems mean that they may not prevent or detect all misstatements, including those arising from human error, circumvention of controls, or fraud.

Future Outlook

This amendment focuses solely on controls and procedures as of December 31, 2025, and does not contain forward-looking financial guidance or outlook statements.

Management Comments

• Management's conclusion that disclosure controls and procedures were effective as of December 31, 2025.
• Management's conclusion that internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2025.
• Acknowledgement that internal control systems have inherent limitations and may not prevent or detect all misstatements.
• Statement that the company cannot assure that material weaknesses or significant deficiencies will not occur in the future.

Industry Context

StockSavvy.ai notes that this filing is a procedural amendment to a Form 10-K, specifically addressing internal controls and procedures. Such amendments are common for ensuring compliance and accuracy in financial reporting, particularly for companies operating in the highly regulated biotechnology sector where robust controls are critical.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence in the accuracy and reliability of the company's public disclosures and financial reporting.
• Management: Reaffirms their responsibility and oversight of the company's control systems.
• Regulators: Ensures compliance with SEC reporting obligations.

Next Steps

• The company will proceed with its 2026 annual meeting of shareholders on June 17, 2026.
• The company will continue to operate under its established disclosure and internal control procedures.

Key Dates

Keywords

10-K/A, Amendment, Adicet Bio, SEC Filing, Disclosure Controls, Internal Controls, Financial Reporting, December 31 2025, Sarbanes-Oxley Act, NASDAQ